From a layman's point of view, the results seem underwhelming. Plus with patent issues and Prosensa/GSK being way ahead in their DMD program, probably a risky investment at this point
Evidently the market agrees with you. I think the 24 week data looks very good.
I prefer seeing the drug work at 24 weeks with only a small gain at 12 weeks, than the other way around.
To me they have learned a lot about the drug to be able to design a phase 3 trial. Isn't that what phase 2's are for?
News 
Market Data 
Discover 
AI
